Home › NDC Lookup › RxCUI directory › RxCUI 849452

Naproxen sodium 500 MG / sumatriptan 85 MG Oral Tablet [Treximet] — RxCUI 849452

RxNorm drug concept · Semantic branded drug
RxCUI 849452 Semantic branded drug · SBD ● Current RxNorm concept 1 FDA product 1 package NDC Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI849452
Official nameNaproxen sodium 500 MG / sumatriptan 85 MG Oral Tablet [Treximet]
Concept typeSemantic branded drug (SBD)
RxNorm statusCurrent RxNorm concept
Also known asTreximet 85/500 (sumitriptan / naproxen sodium) Oral Tablet; Treximet 85 MG / 500 MG Oral Tablet; Treximet (naproxen sodium 500 MG / sumatriptan 85 MG (as sumatriptan succinate 119 MG)) Oral Tablet
FDA products mapped1
Package NDCs mapped1
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Sumatriptan: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • Sumatriptan is specifically for migraine headaches — it's not a general pain reliever like ibuprofen. It's designed to stop a migraine attack once it's already started, with or wit...
  • What exactly is sumatriptan for? Will it work on any headache?
  • You don't need to wait until it's unbearable. Taking sumatriptan at the first sign of a migraine is generally the right move — don't wait it out. That said, it is meant for confirm...
  • When should I take sumatriptan — do I have to wait until the headache is severe?
📖 Read our full Sumatriptan guide →

🕸️ Concept Web — How Naproxen sodium 500 MG / sumatriptan 85 MG Oral... Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Naproxen sodium 500 MG / sumatriptan 85 MG Oral Tablet [Treximet] RxCUI 849452

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 4

    The active substance itself — no strength, form, or brand attached yet.

    • Naproxen 7258
    • Sumatriptan 37418
    • Naproxen / sumatriptan 797426
    • Naproxen sodium 142442
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Treximet 794765
  3. Dose forms 13

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Naproxen / sumatriptan Oral Tablet 794763
    • Naproxen sodium / sumatriptan Oral Tablet 2647518
    • Naproxen / sumatriptan Oral Product 1157005
    • Naproxen / sumatriptan Pill 1157512
    • Naproxen sodium / sumatriptan Oral Product 2661109
    • Naproxen sodium / sumatriptan Pill 2661991
    • Naproxen / sumatriptan Oral Tablet [Treximet] 794767
    • Naproxen sodium / sumatriptan Oral Tablet [Treximet] 2654512
    • +5 more in this family
  4. Clinical & branded drugs 4

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 17 of 22 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Naproxen sodium 500 MG / sumatriptan 85 MG Oral Tablet SCD · 849450
  • Naproxen sodium 500 MG SCDC · 849449
  • Sumatriptan 85 MG SCDC · 644919
  • Naproxen / sumatriptan Oral Tablet SCDF · 794763
  • Naproxen sodium / sumatriptan Oral Tablet SCDFP · 2647518
  • Naproxen / sumatriptan Oral Product SCDG · 1157005
  • Naproxen / sumatriptan Pill SCDG · 1157512
  • Naproxen sodium / sumatriptan Oral Product SCDGP · 2661109
  • Naproxen sodium / sumatriptan Pill SCDGP · 2661991

Brand-Name Concepts

  • Naproxen sodium 500 MG / sumatriptan 85 MG [Treximet] SBDC · 849451
  • Naproxen / sumatriptan Oral Tablet [Treximet] SBDF · 794767
  • Naproxen sodium / sumatriptan Oral Tablet [Treximet] SBDFP · 2654512
  • Treximet Oral Product SBDG · 1179685
  • Treximet Pill SBDG · 1179686
  • Treximet BN · 794765

📦 FDA Products & Package NDCs

1 product · 1 package NDC
1 package NDC map to RxCUI 849452 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
42847-0850-09 9 TABLET, FILM COATED in 1 BOTTLE (42847-850-09) Treximet Currax Pharmaceuticals LLC 2008-04-25
Observed labelers: Currax Pharmaceuticals LLC (1) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.